CJA
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Submit a scholarly reply
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Backman, S. B.
Right arrow Articles by Polosa, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Backman, S. B.
Right arrow Articles by Polosa, C.

Canadian Journal of Anesthesia, Vol 44, 247-254, Copyright © 1997 by Canadian Anesthesiologists' Society

ARTICLES

Heart rate changes in cardiac transplant patients and in the denervated cat heart after edrophonium

SB Backman, RD Stein, GS Fox and C Polosa
Department of Anaesthesia, Royal Victoria Hospital, Montreal, Quebec, Canada.

PURPOSE: The effect of edrophonium on heart rate in cardiac transplant patients and in an animal model of acute cardiac denervation were studied, to evaluate the functional state of the peripheral parasympathetic pathway following cardiac denervation. METHODS: Edrophonium was studied in patients with normally innervated hearts (controls) and in cardiac transplants. Edrophonium was also studied in vagotomized, beta-blocked cats. In Group I animals, the vagus nerve was not stimulated. In Groups 2 & 3 the right vagus nerve was electrically stimulated to produce approximately 20% and 40% reductions in baseline heart rate, respectively. RESULTS: Maximum heart rate reduction in transplants (7.3 +/- 0.8 beats.min-1 with 0.6 +/- 0.08 mg.kg-1) was less than in controls (13.3 +/- 1.6 beats.min-1 with 0.4 + 0.05 mg.kg-1, P < 0.01). In Group I animals heart rate decreased maximally by 20.9 +/- 2.5 beats.min-1 with 9.0 +/- 1.9 mg.kg-1. In Groups 2 and 3, with doses < 1.5 mg.kg-1, reductions in heart rate were greater than in Group I and maximum reductions were obtained with lower doses (Group 2: maximum reduction by 20.3 +/- 2.8 beats.min-1 with 1.3 +/- 0.1 mg.kg-1; Group 3:22.6 +/- 4.0 beats.min-1 with 0.8 +/- 0.2 mg.kg-1, P < 0.001). Doses > 1.5 mg.kg-1 in Groups 2 and 3 produced increases in heart rate. CONCLUSION: Edrophonium produced bradycardia in cardiac transplants suggesting spontaneous release of acetylcholine from parasympathetic postganglionic neurons in the transplanted heart. The magnitude of the bradycardia was less in transplant than in control patients. Findings from animal studies suggest that the reduction in transplants can be attributed to diminution or absence of tonic cardiac parasympathetic drive. At high doses, edrophonium may interfere with parasympathetic neuron activation.


This article has been cited by other articles:


Home page
 Anesth. Analg.Home page
O. Shibata, M. Saito, M. Yoshimura, M. Yamaguchi, T. Makita, and K. Sumikawa
Interactions of Edrophonium with Neostigmine in the Rat Trachea
Anesth. Analg., October 1, 2003; 97(4): 1059 - 1063.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
A. Deschamps, S. B. Backman, V. Novak, G. Plourde, P. Fiset, and D. Chartrand
Effects of the Anticholinesterase Edrophonium on Spectral Analysis of Heart Rate and Blood Pressure Variability in Humans
J. Pharmacol. Exp. Ther., January 1, 2002; 300(1): 112 - 117.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
S. B. Backman and G. Kostopanagiotou
Anticholinesterases and the transplanted heart.
Anesth. Analg., April 1, 2000; 90(4): 1001 - 1001.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1997 by the Canadian Anesthesiologists' Society.